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Background:  Statins are among the most commonly prescribed class of medications. Up to 10% of all patients experience myalgias while on 
statins, according to observational studies. Several small case reports suggest that alternate day dosing regimens of rosuvastatin may reduce the 
incidence of intolerance with acceptable reductions in LDL. Our retrospective case series describes patients previously intolerant of statins who were 
initiated on an alternate day dosing regimen of rosuvastatin, their resulting LDL reductions from baseline, and the tolerability of this dosing regimen.
Methods:  Patients previously intolerant of statins were initiated on alternate day rosuvastatin treatment. We evaluated the tolerability of this 
regimen and the effect on lipid profiles at 6 weeks or more as compared with their baseline lipid profiles.
Results:  The mean dose of rosuvastatin was 5.76 mg three times weekly. 18 patients were prescribed the alternate day dosing regimen. At the 
time of follow-up, 3/18 patients (16.7%) did not have available lipid values recorded, 2/18 patients (11%) were unable to tolerate the regimen, and 
1/18 patients (5.6%) never started therapy. In total, 12/18 patients (67%) were able to continue treatment to follow-up. The mean reduction in LDL 
in these patients was 45% (95% confidence interval 36.8%-53.0%).
Conclusions:  Alternate day rosuvastatin dosing regimens improve tolerability and offer significant LDL reduction in patients unable to tolerate 
daily dosing regiments.
